Last reviewed · How we verify
Ropivacaine 0.2% + Dexamethasone
Ropivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and edema at the injection site.
Ropivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and edema at the injection site. Used for Local and regional anesthesia for surgical procedures, Post-operative pain management.
At a glance
| Generic name | Ropivacaine 0.2% + Dexamethasone |
|---|---|
| Also known as | Do not have |
| Sponsor | Instituto do Coracao |
| Drug class | Local anesthetic with corticosteroid adjuvant |
| Target | Voltage-gated sodium channels (ropivacaine); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing depolarization and conduction of nerve impulses. Dexamethasone, a corticosteroid, is added to reduce post-operative inflammation, pain, and swelling, thereby prolonging the duration and improving the quality of anesthesia.
Approved indications
- Local and regional anesthesia for surgical procedures
- Post-operative pain management
Common side effects
- Transient neurological symptoms
- Hypotension
- Bradycardia
- Nausea
- Headache
- Local tissue irritation
Key clinical trials
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA (NA)
- Impact of Dexamethasone Route on Pain and Inflammation in iPACK With ACB for Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.2% + Dexamethasone CI brief — competitive landscape report
- Ropivacaine 0.2% + Dexamethasone updates RSS · CI watch RSS
- Instituto do Coracao portfolio CI